PAVmed Inc. (PAVM)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1624326 · fiscal year ends in Dec
Closing price $1.95 on 30 Oct 2026; 52-week range $1.95 to $12.87.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $112.0K
- Revenue growth
- -89.0%
- Net income, last twelve months
- -$12.1M
- Earnings per share
- -$4.66
- Gross margin
- -221.4%
- Operating margin
- -23841.1%
- Net margin
- -10794.6%
- Free cash flow
- -$7.8M
- Return on equity
- -34.5%
- Market value
- $12.2M
- Cash
- $3.8M
- Debt
- $15.0M
- Debt to equity
- 0.43
- Shares outstanding
- 6.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $71.0K | -$21.8M | $401.0K | -$1.41 | -$5.2M | 10-K filed 27 Mar 2026 |
| FY2024 | 31 Dec 2024 | $3.0M | -$44.5M | $39.8M | $3.75 | -$33.6M | 10-K filed 24 Mar 2025 |
| FY2023 | 31 Dec 2023 | $2.5M | -$68.8M | -$64.2M | -$68.70 | -$52.3M | 10-K filed 25 Mar 2024 |
| FY2022 | 31 Dec 2022 | $377.0K | -$90.9M | -$89.0M | -$112.73 | -$72.5M | 10-K filed 14 Mar 2023 |
| FY2021 | 31 Dec 2021 | $500.0K | -$54.4M | -$50.3M | -$73.13 | -$42.1M | 10-K filed 6 Apr 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $33.0K | -$5.4M | -$0.87 |
| Q1 FY2026 | 31 Mar 2026 | $22.0K | -$60.0K | -$1.10 |
| Q4 FY2025 | 31 Dec 2025 | $52.0K | -$1.3M | -$0.51 |
| Q3 FY2025 | 30 Sep 2025 | $5.0K | -$5.4M | -$2.17 |
| Q2 FY2025 | 30 Jun 2025 | $6.0K | -$11.9M | -$5.55 |
| Q1 FY2025 | 31 Mar 2025 | $8.0K | $19.0M | $2.55 |
| Q4 FY2024 | 31 Dec 2024 | $0 | $1.4M | $0.90 |
| Q3 FY2024 | 30 Sep 2024 | $1.0M | $64.4M | $10.80 |
Company events
The newest 8-K filings of 187 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Oct 2026 | 8-K | Material agreement, Shareholder rights change | 1.01, 3.03, 9.01 |
| 10 Sep 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 14 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 24 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 15 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 30 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 27 Mar 2026 | 8-K | Leadership change, Shareholder vote, Bylaws or fiscal year change | 5.02, 5.03, 5.07, 9.01 |
| 4 Feb 2026 | 8-K | Material agreement, Agreement ended, New debt, Share sale, Shareholder rights change, Bylaws or fiscal year change, Investor update | 1.01, 1.02, 2.03, 3.02, 3.03, 5.03, 7.01, 9.01 |
| 23 Jan 2026 | 8-K | Other events | 8.01, 9.01 |
| 30 Dec 2025 | 8-K | Shareholder rights change, Bylaws or fiscal year change, Investor update | 3.03, 5.03, 7.01, 9.01 |
| 5 Dec 2025 | 8-K | Shareholder vote | 5.07, 9.01 |
| 13 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 430 held.
| Filed | Form | Period |
|---|---|---|
| 22 Oct 2026 | 8-K | 21 Oct 2026 |
| 10 Sep 2026 | 8-K | 9 Sep 2026 |
| 14 Aug 2026 | 8-K | 14 Aug 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 30 Jul 2026 | S-8 | – |
| 24 Jun 2026 | 8-K | 24 Jun 2026 |
| 15 May 2026 | 8-K | 15 May 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | DEF 14A | 30 Apr 2026 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 29 Apr 2026 | EFFECT | – |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 23 Oct 2026 | Kallman Craig | 13G amended | 4.9% | 399.8K |
| 13 Aug 2026 | NAGELBERG DAVID S | 13G amended | 8.8% | 699.8K |
| 15 May 2026 | Two Seas Capital LP | 13G | 9.99% | 657.2K |
| 14 May 2026 | FIRST MANHATTAN CO. LLC. | 13G | 9.6% | 639.2K |
| 11 May 2026 | Ayrton Capital LLC | 13G amended | 9.99% | 709.1K |
| 14 Apr 2026 | Tasso Partners, LLC | 13G amended | 15.3% | 974.2K |
| 13 Apr 2026 | Scopia Holdings LLC | 13G | 9.9% | 637.7K |
| 9 Apr 2026 | Aklog Lishan | 13D | 5.1% | 369.1K |
| 8 Apr 2026 | NAGELBERG DAVID S | 13G | 8.6% | 547.0K |
| 8 Apr 2026 | Dols Scott V. | 13G | 5.4% | 346.2K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 12.7K | +0.76% | 1 |
| 30 Sep 2026 | 12.6K | +16.68% | 1 |
| 15 Sep 2026 | 10.8K | +36.25% | 1 |
| 31 Aug 2026 | 7.9K | -64.96% | 1 |
| 14 Aug 2026 | 22.7K | +10.96% | 1 |
| 31 Jul 2026 | 20.4K | -25.38% | 1.53 |
| 15 Jul 2026 | 27.4K | -18.68% | 2.18 |
| 30 Jun 2026 | 33.6K | +299.74% | 1 |
Funds that hold it
From each fund's latest Form 13F.
24 funds held it at 30 Jun 2026: 11 added and 3 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Two Seas Capital LP | 461,539 | $2.7M | 0 |
| First Manhattan Co. LLC. | 332,911 | $2.0M | +309,106 |
| Vanguard Capital Management LLC | 61,604 | $365.9K | +55,687 |
| Geode Capital Management, LLC | 36,678 | $217.9K | +24,901 |
| Vanguard Fiduciary Trust Co. | 25,605 | $152.1K | +20,176 |
| BlackRock, Inc. | 17,092 | $101.5K | +14,676 |
| Morgan Stanley | 163 | $968 | -2 |
| Barclays PLC | 75 | $446 | +75 |
| SBI Securities Co., Ltd. | 67 | $398 | 0 |
| UBS Group AG | 57 | $339 | -18 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B